Epidemiological and Clinical Characteristics of Non-neonatal Tetanus Patients in Guangxi, China: An 11-year Retrospective Study (2011–2021)

KANG Yi Wen MAI Guo Feng ZHU Xiao Ling DENG Shang Qin YANG Shi Xiong TENG Hong Li YUAN Zong Xiang MO Chu Ye LIN Jian Yan YE Li TANG Hua Min

KANG Yi Wen, MAI Guo Feng, ZHU Xiao Ling, DENG Shang Qin, YANG Shi Xiong, TENG Hong Li, YUAN Zong Xiang, MO Chu Ye, LIN Jian Yan, YE Li, TANG Hua Min. Epidemiological and Clinical Characteristics of Non-neonatal Tetanus Patients in Guangxi, China: An 11-year Retrospective Study (2011–2021)[J]. Biomedical and Environmental Sciences, 2023, 36(9): 880-885. doi: 10.3967/bes2023.113
Citation: KANG Yi Wen, MAI Guo Feng, ZHU Xiao Ling, DENG Shang Qin, YANG Shi Xiong, TENG Hong Li, YUAN Zong Xiang, MO Chu Ye, LIN Jian Yan, YE Li, TANG Hua Min. Epidemiological and Clinical Characteristics of Non-neonatal Tetanus Patients in Guangxi, China: An 11-year Retrospective Study (2011–2021)[J]. Biomedical and Environmental Sciences, 2023, 36(9): 880-885. doi: 10.3967/bes2023.113

doi: 10.3967/bes2023.113

Epidemiological and Clinical Characteristics of Non-neonatal Tetanus Patients in Guangxi, China: An 11-year Retrospective Study (2011–2021)

Funds: This research was supported by Guangxi Health Commission Project [No.Z20200514] and Guangxi Science and Technology Base and Talent Project [No. AD22035052].
More Information
    Author Bio:

    KANG Yi Wen, female, born in 1997, Postgraduate Student, majoring in epidemiology

    MAI Guo Feng, female, born in 1995, Graduate Student, majoring in emergency medicine

    ZHU Xiao Ling, female, born in 1985, Graduate Student, majoring in emergency treatment in critical condition

    Corresponding author: LIN Jian Yan, E-mail: linjianyan@126.comYE Li, E-mail: yeli@gxmu.edu.cnTANG Hua Min, E-mail: sam20041188@163.com
  • &These authors contributed equally to this work.
  • &These authors contributed equally to this work.
    注释:
  • Figure  1.  Trend of case fatality in non-neonatal tetanus patients over time (by year).

    S1.  Temporal distribution of non-neonatal tetanus cases from July 2011 to July 2021. (A) The time of disease onset of non-neonatal tetanus patients (month, year). (B) Trend in the number of non-neonatal tetanus cases over time (by year).

    S1.   Grading of the severity of tetanus according to the Ablett scale

    GradeTrismusSpasmsDysphagiaRespiratory embarrassmentAutonomic nervous dysfunction
    IMild to moderateNoLittle or noNoNo
    IIModerateMild to moderate but shortMildRespiratory rate 30–40No
    IIISevereSevere, persistentSevereRespiratory rate > 40, apnoeic spellsTachycardia > 120
    IVSevereSevere, persistentSevereRespiratory rate > 40, apnoeic spellsSevere hypertension, tachycardia, hypotension, bradycardia
    下载: 导出CSV

    Table  1.   Basic characteristics and clinical data of patients with non-neonatal tetanus

    CharacteristicsNumber of casesComposition ratio (%)
    GenderMale12251.69
    Female11448.31
    Age [years, M (IQR)]Male56.00 (20.25)
    Female67.00 (19.00)
    OccupationFarmer16067.80
    Worker2611.02
    Retiree218.90
    Laid-off or unemployed145.93
    Fisherman62.54
    Freelance62.54
    Children20.84
    Professional skill worker10.42
    ResidenceUrban6728.39
    Rural16971.61
    Tetanus toxoid vaccinationNil21691.53
    Completed208.47
    Pathogenic factorsIdentified21189.41
    Traumatism19180.93
    Other risk factors208.47
    Unidentified2510.59
    Injury sitesLower extremity10644.92
    Upper extremity6326.69
    Head and neck3113.14
    Other sites3615.25
    Incubation period [d, M (IQR)]Head and neck5.00 (6.00)
    Trunk30.00 (0.00)
    Upper extremity7.00 (5.00)
    Lower extremity9.50 (10.25)
    Multiple sites7.00 (10.50)
    Initial diagnosisYes3213.56
    No20486.44
    The level of health facilities for initial visitProvince-level10142.80
    City-level6728.39
    County-level4418.64
    Private/village2410.17
    Time from onset to initial visit [d, M (IQR)]2.00 (4.00)
    First symptomsTrismus19984.32
    Muscle spasms93.81
    Myodynia62.54
    Nuchal rigidity41.70
    Dysphagia41.70
    Other symptom145.93
    Co-morbiditiesYes19582.63
    No4117.37
    ComplicationsYes19582.63
    No4117.37
    Length of a hospital stay [d, M (IQR)]16.00 (18.00)
    Hospitalization expenses [RMB, M (IQR)]20,200.34 (3,659.10)
    Payment methodSelf-paying13155.51
    Resident basic medical insurance5222.03
    Rural cooperative medical insurance4318.22
    Others104.24
    ICU admissionYes6125.85
    No17574.15
    Tracheal intubation or tracheotomyYes8033.90
    No15666.10
    下载: 导出CSV

    S2.   Comparison of latency at different etiological sites in non-neonatal tetanus patients

    Variables Head and neck Trunk Upper extremity Lower extremity Multiple sites χ2 value P value
    Incubation period [M (IQR)] 5.00 (6.00)a 30.00 (0.00) 7.00 (5.00) 9.50 (10.25) 7.00 (10.50) 18.39 < 0.01
      Note. Kruskal–Wallis test was used to compare incubation period among different etiological sites. aCompared with lower limb group.
    下载: 导出CSV

    S3.   Co-morbidities and complications of patients with non-neonatal tetanus

    Characteristics Number of cases (persons) Composition ratio (%)
    Co-morbidities Hypertension 24 10.17
    Tuberculosis 21 8.90
    Cerebrovascular disease 17 7.20
    Chronic liver disease 14 5.93
    Coronary artery disease 7 2.97
    Diabetes 7 2.97
    Cancer 6 2.54
    AIDS 6 2.54
    Heart valve diseases 4 1.70
    Autoimmune rheumatic disease 4 1.70
    Arrhythmia 2 0.85
    Complications Secondary infection 159 67.37
    Respiratory failure 45 19.07
    Electrolyte disturbances 38 16.10
    Hypoalbuminemia 34 14.41
    Hypohepatia 31 13.13
    Myocardial injury 22 9.32
    Autonomic dysfunction 16 6.78
    Renal insufficiency 11 4.66
    Asphyxia 9 3.81
    Hypoxic-ischemic encephalopathy 8 3.39
    Sepsis 7 2.97
    Cardiac failure 5 2.11
    Acute pancreatitis 5 2.11
    Gastrointestinal hemorrhage 4 1.70
    Coagulation dysfunction 4 1.70
    Toxic encephalopathy 3 1.27
    Acute myocardial infarction 3 1.27
    Pressure ulcer 3 1.27
    Thrombogenesis 2 0.85
    下载: 导出CSV

    Table  2.   Risk factors on grading disease severity in non-neonatal tetanus patients

    Variables Grading of disease severity Univariate analysis Multivariate
    analysis
    Grade I, n (%) Grade II, n (%) Grade III, n (%) Grade IV, n (%) χ2 value P value OR (95% CI) P value
    Age [years, M (IQR)] 59.50 (19.25) 59.00 (21.25) 66.00 (19.25) 58.50 (23.50) 2.52 0.47
    Time from onset to initial visit
    [d, M (IQR)]
    3.50 (6.00) 3.00 (4.00) 2.00 (2.00) 1.00 (1.00) 16.43 < 0.01 0.97 (0.89, 1.06) 0.50
    Incubation period [d, M (IQR)] 7.00 (9.00) 9.00 (11.00) 7.00 (5.00) 6.50 (10.00) 10.44 0.02 1.00 (1.00, 1.00) 0.07
    Gender 0.16 0.98
    Male 26 (21.31) 56 (45.90) 31 (25.41) 9 (7.38)
    Female 24 (21.05) 54 (47.37) 29 (25.44) 7 (6.14)
    Forms of tetanus 50.62 < 0.01
    Localized/cerebral 22(81.48) 4 (14.82) 1 (3.70) 0 (0.00) 1.00
    Systemic 28 (13.40) 106 (50.72) 59 (28.23) 16 (7.65) 26.79 (9.24, 77.63) < 0.01
    Co-morbidities
    Chronic liver disease 1 (7.14) 9 (64.29) 3 (21.43) 1 (7.14) 2.36 0.47
    Tuberculosis 5 (23.81) 8 (38.10) 7 (33.33) 1 (4.76) 1.20 0.76
    Hypertension 3 (12.50) 11 (45.83) 8 (33.33) 2 (8.33) 1.88 0.60
    Coronary artery disease 1 (14.29) 3 (42.86) 2 (28.57) 1 (14.29) 1.49 0.71
    Heart valve diseases 2 (50.00) 0 (0.00) 2 (50.00) 0 (0.00) 4.88 0.13
    Arrhythmia 0 (0.00) 1 (50.00) 1 (50.00) 0 (0.00) 1.68 1.00
    Autoimmune rheumatic disease 1 (25.00) 2 (50.00) 1 (25.00) 0 (0.00) 0.65 1.00
    Cerebrovascular disease 5 (29.41) 5 (29.41) 5 (29.41) 2 (11.77) 3.19 0.33
    Diabetes 0 (0.0) 2 (28.57) 3 (42.86) 2 (28.57) 6.53 0.05 0.15 (0.03, 0.72) 0.02
    Cancer 4 (66.67) 0 (0.00) 0 (0.00) 2 (33.33) 13.57 < 0.01 3.32 (0.46, 23.81) 0.23
    AIDS 0 (0.00) 3 (50.00) 2 (33.33) 1 (16.67) 2.78 0.35
    下载: 导出CSV

    S4.   Univariate analysis of risk factors of disease outcome in non-neonatal tetanus patients

    VariablesOutcomeχ2/Z valueP value
    Died, n (%)Alive, n (%)
    Age [years, M (IQR)]63.00 (23.00)60.00 (20.00)−1.24a0.22
    Time from onset to initial visit [d, M (IQR)]1.00 (1.00)3.00 (4.00)−3.22a< 0.01
    Incubation period [d, M (IQR)]5.50 (7.00)8.00 (10.00)−2.43a0.02
    Gender0.18b0.67
    Male15 (12.30)107 (87.70)
    Female12 (10.53)102 (89.47)
    Forms of tetanus2.77b0.10
    Systemic27(12.92)182 (87.08)
    Localized/Cerebral0 (0.00)27 (100.00)
    ICU admission1.99b0.16
    No17 (9.71)158 (90.29)
    Yes10 (16.39)51 (83.61)
    Tracheal intubation or tracheotomy18.10b< 0.01
    No8 (5.13)148 (94.87)
    Yes19 (23.75)61 (76.25)
    Grading of disease severity64.80b< 0.01
    I0 (0.00)50 (100.00)
    II1 (0.91)109 (99.09)
    III15 (25.00)45 (75.00)
    IV11 (68.75)5 (31.25)
    Co-morbidities
    Chronic liver disease1 (7.14)13 (92.86)0.01b0.93
    Tuberculosis0 (0.00)21 (100.00)1.87b0.17
    Hypertension2 (8.33)22 (91.67)0.03b0.87
    Coronary artery disease1 (14.29)6 (85.71)0.58
    Heart valve diseases0 (0.00)4 (100.00)1.00
    Arrhythmia0 (0.00)2 (100.00)1.00
    Autoimmune rheumatic disease0 (0.00)4 (100.00)1.00
    Cerebrovascular disease3 (17.65)14 (82.35)0.19b0.66
    Diabetes3 (42.86)4 (57.14)0.03
    Cancer2 (33.33)4 (66.67)0.14
    AIDS2 (33.33)4 (66.67)0.14
    Complications
    Hypoxic-ischemic encephalopathy4 (50.00)4 (50.00)0.01
    Toxic encephalopathy0 (0.00)3 (100.00)1.00
    Secondary infection24 (15.09)135 (84.91)6.42b0.01
    Respiratory failure21 (46.67)24 (53.33)68.10b< 0.01
    Asphyxia8 (88.89)1 (11.11)47.73b< 0.01
    Cardiac failure3 (60.00)2 (40.00)0.01
    Myocardial injury6 (27.27)16 (72.73)4.40b0.04
    Acute myocardial infarction2 (66.67)1 (33.33)0.04
    Gastrointestinal hemorrhage0 (0.00)4 (100.00)1.00
    Acute pancreatitis3 (60.00)2 (40.00)0.01
    Hypohepatia6 (19.35)25 (80.65)1.40b0.24
    Renal insufficiency7 (63.64)4 (36.36)25.86b< 0.01
    Electrolyte disturbances6 (15.79)32 (84.21)0.41b0.52
    Hypoalbuminemia5 (14.71)29 (85.29)0.13b0.72
    Coagulation dysfunction0 (0.00)4 (100.00)1.00
    Pressure ulcer1 (33.33)2 (66.67)0.31
    Sepsis2 (28.57)5 (71.43)0.19
    Thrombogenesis0 (0.00)2 (100.00)1.00
      Note. aRepresents the Z values derived from Mann-Whitney U test. bRepresents the χ2 values derived from chi-squared test. Fisher’s exact probability test was used for the remaining variables.
    下载: 导出CSV

    S5.   Binary logistic regression analysis of risk factors for disease outcome in non-neonatal tetanus patients

    VariablesOR95% CIP value
    Time from onset to initial visit1.11(0.91, 1.36)0.30
    Incubation period1.00(0.99, 1.01)0.72
    Tracheal intubation or tracheotomy0.36(0.02, 6.58)0.49
    Grading of disease severity54.97(5.55, 544.15)< 0.01
    Diabetes13.72(0.61, 310.75)0.10
    Hypoxic-ischemic encephalopathy0.44(0.03, 6.51)0.55
    Secondary infection0.12(0.00, 19.36)0.41
    Respiratory failure14.19(1.84, 109.36)0.01
    Asphyxia84.18(3.62, 1,959.83)< 0.01
    Cardiac failure279.68(4.31, 18,140.28)< 0.01
    Myocardial injury0.41(0.02, 8.54)0.56
    Acute myocardial infarction19.21(0.04, 9,514.50)0.35
    Acute pancreatitis8.60(0.43, 172.56)0.16
    Renal insufficiency84.45(2.30, 3,104.41)0.02
    下载: 导出CSV

    S6.   Correlation analysis of grading of disease severity in non-neonatal tetanus patients

    Variablesr value
    Length of hospital stay0.28*
    Hospitalization expenses0.41*
    ICU admission rate0.58*
    Tracheal intubation or tracheotomy rate0.71*
      Note. Spearman analysis was used for the correlation analysis. *P value < 0.05.
    下载: 导出CSV
  • [1] Farrar JJ, Yen LM, Cook T, et al. Tetanus. J Neurol Neurosurg Psychiatry, 2000; 69, 292−301. doi:  10.1136/jnnp.69.3.292
    [2] Finkelstein P, Teisch L, Allen CJ, et al. Tetanus: a potential public health threat in times of disaster. Prehosp Disaster Med, 2017; 32, 339−42. doi:  10.1017/S1049023X17000012
    [3] Kyu HH, Mumford JE, Stanaway JD, et al. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health, 2017; 17, 179. doi:  10.1186/s12889-017-4111-4
    [4] Woldeamanuel YW, Andemeskel AT, Kyei K, et al. Case fatality of adult tetanus in Africa: systematic review and meta-analysis. J Neurol Sci, 2016; 368, 292−9. doi:  10.1016/j.jns.2016.07.025
    [5] Centers for Disease Control and Prevention. Tetanus surveillance --- United States, 2001-2008. MMWR Morb Mortal Wkly Rep, 2011; 60, 365-9.
    [6] World Health Organization. Non-neonatal tetanus. 2018. https://www.who.int/docs/default-source/immunization/vpd_surveillance/vpd-surveillance-standards-publication/who-surveillancevaccinepreventable-15-nonneonataltetanus-r2.pdf?sfvrsn=1934e2a1_10&download=true. [2023-01-16
    [7] Wang CL, Liu S, Chen QJ, et al. Guidance for diagnosis and treatment of non-neonatal tetanus. Chin J Vaccines Immun, 2020; 26, 228−31, 240. (In Chinese
    [8] Wei JG, Wang SX, Qin H. Epidemiological characteristics and death risk analysis of severe tetanus in a tertiary hospital, 2008-2018. Pract Prev Med, 2020; 27, 50−3. (In Chinese
    [9] Wang TT, Gao Y, Duan YX, et al. Investigation on antibody level of pertussis diphtheria tetanus in healthy population in nanshan district in Shenzhen in 2018. J Prev Med Inf, 2020; 36, 326−31. (In Chinese
    [10] Amare A, Melkamu Y, Mekonnen D. Tetanus in adults: clinical presentation, treatment and predictors of mortality in a tertiary hospital in Ethiopia. J Neurol Sci, 2012; 317, 62−5. doi:  10.1016/j.jns.2012.02.028
  • [1] HOU Yu Shan, JIN Yi Chen, CAI Chang, TANG Hou Lin, QIN Qian Qian, LYU Fan.  Characteristics of the HIV/AIDS Epidemic among People Aged ≥ 50 Years in China during 2018–2021 . Biomedical and Environmental Sciences, 2024, 37(4): 399-405. doi: 10.3967/bes2024.044
    [2] ZHANG Lei, GAI Xiao Yan, LI Xin, LIANG Ying, WANG Meng, ZHAO Fei Fan, ZHOU Qing Tao, SUN Yong Chang.  Influence of the Pre-shock State on the Prognosis of Medical Patients with Sepsis: A Retrospective Cohort Study . Biomedical and Environmental Sciences, 2023, 36(12): 1152-1161. doi: 10.3967/bes2023.150
    [3] CHEN Qiu Li, LIAO Yan Yan, QIN Shan Fang, LU Chun Yan, PAN Pei Jiang, WANG Hai Long, JIANG Jun Jun, ZHENG Zhi Gang, QIN Feng Xiang, HONG Wen, NING Chuan Yi, YE Li, LIANG Hao.  Effects of Differential First-Line Antiretroviral Therapy (ART) Regimens on Mortality among HIV/AIDS Children in Southwest China: A 15-year Retrospective Cohort Study . Biomedical and Environmental Sciences, 2023, 36(11): 1079-1083. doi: 10.3967/bes2023.137
    [4] DING Rui, MA Rui Rui, LIU Ya Li, ZHAO Ying, GUO Li Na, DOU Hong Tao, SUN Hong Li, LIU Wen Jing, ZHANG Li, WANG Yao, LI Ding Ding, YI Qiao Lian, XU Ying Chun.  Causative Microorganisms Isolated from Patients with Intra-Abdominal Infections and Their Drug Resistance Profiles: An 11-Year (2011–2021) Single-Center Retrospective Study . Biomedical and Environmental Sciences, 2023, 36(8): 732-742. doi: 10.3967/bes2023.072
    [5] XIONG Yi Bai, TIAN Ya Xin, MA Yan, YANG Wei, LIU Bin, RUAN Lian Guo, LU Cheng, HUANG Lu Qi.  Factors Defining the Development of Severe Illness in Patients with COVID-19: A Retrospective Study . Biomedical and Environmental Sciences, 2021, 34(12): 984-991. doi: 10.3967/bes2021.117
    [6] YANG Zhi Hui, SONG Ying Gai, LI Ruo Yu.  A Ten-year Retrospective Study of Invasive Candidiasis in a Tertiary Hospital in Beijing . Biomedical and Environmental Sciences, 2021, 34(10): 773-788. doi: 10.3967/bes2021.107
    [7] WU Yue, LI Zhen Jun, YU Shi Cheng, CHEN Liang, WANG Ji Chun, QIN Yu, SONG Yu Dan, George F. GAO, DONG Xiao Ping, WANG Li Ping, ZHANG Qun, HE Guang Xue.  Epidemiological Characteristics of Notifiable Infectious Diseases among Foreign Cases in China, 2004–2017 . Biomedical and Environmental Sciences, 2020, 33(6): 421-430. doi: 10.3967/bes2020.057
    [8] CHE Chun Li, DONG Fu Shi, LI Jia Lin, ZHANG Chun Ling, LIU Lu, WU Yu Han, WANG Kun, QI Hong.  Retrospective Study of Effect of Fine Particulate Matter on Acute Exacerbation of Patients with Idiopathic Pulmonary Fibrosis . Biomedical and Environmental Sciences, 2020, 33(2): 138-140. doi: 10.3967/bes2020.018
    [9] WANG Fang, LAI Chang Xiang, HUANG Peng Yu, LIU Jia Ming, WANG Xian Feng, TANG Qi Yuan, ZHOU Xuan, XIAN Wen Jie, CHEN Rui Kun, LI Xuan, LI Zhi Yu, LIAO Li Qun, HE Qing, LIU Lei.  Comparison of Clinical Characteristics and Outcomes of Pediatric and Adult Patients with Coronavirus Disease 2019 in Shenzhen, China . Biomedical and Environmental Sciences, 2020, 33(12): 906-915. doi: 10.3967/bes2020.124
    [10] DONG Jing Xiao, LI Ao Fei, LI Run Qing, CHAO Shuang, YANG Song, ZHAO Xiu Ying.  Epidemiological and Clinical Features of Rotavirus and Adenovirus Related Gastroenteritis in Beijing: A Retrospective Case-control Study in Pediatric Patients . Biomedical and Environmental Sciences, 2020, 33(3): 196-200. doi: 10.3967/bes2020.027
    [11] ZHAO Xiu Ying, ZENG Zhao Ying, HUA Wen Hao, YU Yan Hua, GUO Cai Ping, ZHAO Xiu Qin, DONG Hai Yan, LIU Jie, WAN Kang Lin.  A Retrospective Study of Culture-confirmed Mycobacterial Infection among Hospitalized HIV-infected Patients in Beijing, China . Biomedical and Environmental Sciences, 2018, 31(6): 459-462. doi: 10.3967/bes2018.060
    [12] LI Fu, LI Gui Lian, PANG Hui, LIU Hai Can, XIAO Tong Yang, LI Shuang Jun, LUO Qiao, JIANG Yi, WANG Rui Bai, WAN Kang Lin.  Preliminary Study on Drug Susceptibility Profile and Resistance Mechanisms to Macrolides of Clinical Isolates of Non-tuberculous Mycobacteria from China . Biomedical and Environmental Sciences, 2018, 31(4): 290-299. doi: 10.3967/bes2018.037
    [13] HE Huan, ZHEN Qing, LI Yong, KOU Chang Gui, TAO Yu Chun, WANG Chang, JosepHSam Kanu, LU Yu Ping, YU Ming Xi, ZHANG Hui Ping, YU Ya Qin, LI Bo, LIU Ya Wen.  Prevalence of High Non-high-density Lipoprotein Cholesterol and Associated Risk Factors in Patients with Diabetes Mellitus in Jilin Province, China:A Cross-sectional Study . Biomedical and Environmental Sciences, 2016, 29(7): 534-538. doi: 10.3967/bes2016.071
    [14] LI Jun Jian, LI Wei, XU Guang Rong, XU Ke Jun, YE Ping, QUAN Yu, NING Rong Bing, GAO Hai Jun, HE Qian Jun, ZHOU Ying, WU Wei Ping.  Analysis on Serum Trace Element Levels of Echinococciasis Patients in Garze Tibetan Autonomous Prefecture in Sichuan, China, 2011 . Biomedical and Environmental Sciences, 2015, 28(9): 683-686. doi: 10.3967/bes2015.096
    [15] MA Li, BAI Ya Na, PU Hong Quan, HE Jie, Bryan A.Bassig, DAI Min, ZHANG Ya Wei, ZHENG Tong Zhang, CHENG Ning.  A Retrospective Cohort Mortality Study in Jinchang, the Largest Nickel Production Enterprise in China . Biomedical and Environmental Sciences, 2014, 27(7): 567-571. doi: 10.3967/bes2014.088
    [16] YOU Yuan Hai, SONG Yan Yang, YAN Xiao Mei, WANG Hai Bin, ZHANG Meng Han, TAO Xiao Xia, LI Lei Lei, ZHANG Yu Xin, JIANG Xi Hong, ZHANG Bing Hua, ZHOU Hao, XIAO Di, JIN Lian Mei, FENG Zi Jian, LUO Feng Ji, ZHANG Jian Zhong.  Molecular Epidemiological Characteristics of Streptococcus pyogenes Strains Involved in an Outbreak of Scarlet Fever in China, 2011 . Biomedical and Environmental Sciences, 2013, 26(11): 877-885. doi: 10.3967/bes2013.016
    [17] HU Ming, HU Guo Qing, SUN Zhen Qiu, HE Xiang.  Epidemiological Survey of the Prevalence of Non-fatal Injury among Children Aged 5-14 Years in China . Biomedical and Environmental Sciences, 2012, 25(4): 407-412. doi: 10.3967/0895-3988.2012.04.005
    [18] ZHANG Li, LUAN Rong Sheng, JIANG Feng, RUI Li Ping, LIU Min, LI Yi Xing, YIN Zun Dong, LUO Hui Min.  Epidemiological Characteristics of Japanese Encephalitis in Guizhou Province,China, 1971-2009 . Biomedical and Environmental Sciences, 2012, 25(3): 297-304. doi: 10.3967/0895-3988.2012.03.007
    [19] SHI Qi, CHEN Cao, GAO Chen, TIAN Chan, ZHOU Wei, ZHANG BaoYun, HAN Jun, DONG Xiao Ping.  Clinical and Familial Characteristics of Ten Chinese Patients with Fatal Family Insomnia . Biomedical and Environmental Sciences, 2012, 25(4): 471-475. doi: 10.3967/0895-3988.2012.04.013
    [20] Jin Zhang, LAN CHEN, BAO-YUN ZHAN, JUN HAN, XIN-LI XIAO, HAI-YAN TIAN, BIN-LING LI, CHEN GAO, JIAN-MEI GAO, Xiao-Bo Zhou, GUI-PING MA, YONG LIU, CAI-MIN XU, XIAO-PING DONG.  Comparison Study on Clinical and Neuropathological Characteristics of Hamsters Inoculated With Scrapie Strain 263K in Different Challenging Pathways . Biomedical and Environmental Sciences, 2004, 17(1): 65-78.
  • 23073+Supplementary Materials.pdf
  • 加载中
图(2) / 表ll (8)
计量
  • 文章访问数:  247
  • HTML全文浏览量:  107
  • PDF下载量:  36
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-03-19
  • 录用日期:  2023-07-14
  • 网络出版日期:  2023-11-02
  • 刊出日期:  2023-09-20

Epidemiological and Clinical Characteristics of Non-neonatal Tetanus Patients in Guangxi, China: An 11-year Retrospective Study (2011–2021)

doi: 10.3967/bes2023.113
    基金项目:  This research was supported by Guangxi Health Commission Project [No.Z20200514] and Guangxi Science and Technology Base and Talent Project [No. AD22035052].
    作者简介:

    KANG Yi Wen, female, born in 1997, Postgraduate Student, majoring in epidemiology

    MAI Guo Feng, female, born in 1995, Graduate Student, majoring in emergency medicine

    ZHU Xiao Ling, female, born in 1985, Graduate Student, majoring in emergency treatment in critical condition

    通讯作者: LIN Jian Yan, E-mail: linjianyan@126.comYE Li, E-mail: yeli@gxmu.edu.cnTANG Hua Min, E-mail: sam20041188@163.com
注释:

English Abstract

KANG Yi Wen, MAI Guo Feng, ZHU Xiao Ling, DENG Shang Qin, YANG Shi Xiong, TENG Hong Li, YUAN Zong Xiang, MO Chu Ye, LIN Jian Yan, YE Li, TANG Hua Min. Epidemiological and Clinical Characteristics of Non-neonatal Tetanus Patients in Guangxi, China: An 11-year Retrospective Study (2011–2021)[J]. Biomedical and Environmental Sciences, 2023, 36(9): 880-885. doi: 10.3967/bes2023.113
Citation: KANG Yi Wen, MAI Guo Feng, ZHU Xiao Ling, DENG Shang Qin, YANG Shi Xiong, TENG Hong Li, YUAN Zong Xiang, MO Chu Ye, LIN Jian Yan, YE Li, TANG Hua Min. Epidemiological and Clinical Characteristics of Non-neonatal Tetanus Patients in Guangxi, China: An 11-year Retrospective Study (2011–2021)[J]. Biomedical and Environmental Sciences, 2023, 36(9): 880-885. doi: 10.3967/bes2023.113
  • Tetanus is the only non-communicable disease among vaccine-preventable infectious diseases. It is caused by an infection with Clostridium tetanus bacterium and is characterized by continuous tonic contraction and paroxysmal spasms of skeletal muscles throughout the body[1]. Tetanus has a relatively high incidence in developing countries, economically impoverished areas, and areas prone to natural disasters[2]. Tetanus is a serious and potentially fatal disease with diverse pathogenic factors. Without any treatment, the case fatality is nearly 100%. Despite aggressive treatment, tetanus still results in 10,000 to 300,000 deaths annually, with the case fatality ranging from 5% to 48%[3,4]. Moreover, the pathogenic tetanus bacteria are widely present in the natural environment and the gastrointestinal tract of animals[1,5]. This widespread presence makes it difficult to avoid exposure, rendering the eradication of tetanus futile.

    According to the data jointly released by World Health Organization (WHO) and United Nations International Children’s Emergency Fund (UNICEF), among the reported tetanus cases globally in 2016, 85% were non-neonatal tetanus[6]. China lacks a comprehensive epidemiological surveillance and reporting system for non-neonatal tetanus. Data on the epidemiological characteristics and disease burden of non-neonatal tetanus are insufficient. In China, most non-neonatal tetanus cases occur in townships and rural areas, and the reported prevalence may be underestimated due to inadequate awareness and monitoring of non-neonatal tetanus in primary healthcare facilities[7]. There is still a wide gap in the reported case fatality rates of tetanus between China and developed countries, indicating that China still faces challenges in managing non-neonatal tetanus[5,8].

    This study aimed to analyze the clinical characteristics and hospitalization costs of non-neonatal tetanus by collecting data from patients diagnosed with the disease over an 11-year period in Guangxi, an economically underdeveloped province in southwest China. Additionally, the study sought to explore potential risk factors associated with disease severity and fatality, with the objective of providing a scientific basis for the prevention, early diagnosis, and treatment of non-neonatal tetanus.

    This retrospective study was conducted on 236 confirmed non-neonatal tetanus patients admitted to three hospitals in Guangxi, China, including Guangxi International Zhuang Medical Hospital, Fourth People’s Hospital of Nanning, and the Second Affiliated Hospital of Guangxi Medical University from July 2011 to July 2021. The inclusion criteria were as follows: patients were older than 28 days, met the diagnostic criteria for tetanus, and case data were complete. At least one of the following diagnostic criteria applied: (1) Lockjaw or grimace; (2) painful muscle spasms.

    Medical records of 236 patients were collected from the hospital’s case system. The information obtained included: sex, age, date of birth, occupation, residence, time of admission, vaccination history, pathogenic factors, etiological types, injury sites, etiological management, whether to prevent tetanus, incubation period, first symptoms, time from onset to the initial visit, whether to first visit and hospital level of initial visit, co-morbidities and complications, forms of tetanus, grading of disease severity, passive immunization drug use, tracheal intubation or tracheotomy, admission of intensive care unit (ICU), length of a hospital stay, outcome, cause of death, type of insurance, hospitalization expenses, etc. The outcome variables for this study included categorizing non-neonatal tetanus cases into groups I, II, III, and IV based on the Ablett scale[7] (Supplementary Table S1, available in www.besjournal.com), as well as the death or survival outcome.

    Table S1.  Grading of the severity of tetanus according to the Ablett scale

    GradeTrismusSpasmsDysphagiaRespiratory embarrassmentAutonomic nervous dysfunction
    IMild to moderateNoLittle or noNoNo
    IIModerateMild to moderate but shortMildRespiratory rate 30–40No
    IIISevereSevere, persistentSevereRespiratory rate > 40, apnoeic spellsTachycardia > 120
    IVSevereSevere, persistentSevereRespiratory rate > 40, apnoeic spellsSevere hypertension, tachycardia, hypotension, bradycardia

    The sociodemographic and clinical variables were analyzed using descriptive statistics. Quantitative data were expressed as median and interquartile range [M (IQR)], and comparison between groups was performed by the Mann-Whitney U and Kruskal-Wallis tests. Qualitative data were expressed as percentage or component ratio (%), and comparison between groups was performed by chi-squared test or Fisher’s exact probability test. The trend test was performed using Spearman analysis. Univariate analysis, binary or ordered logistic multivariate regression models were used for influencing factor analysis. Odds ratio (OR) and confidence interval (95% Cl) were used to assess the risk and prognostic factors of non-neonatal tetanus. A significance level of P < 0.05 was used for all tests to determine statistical significance. SPSS statistical software version 26.0 was used for statistics and analysis.

    The sociodemographic characteristics of the patients are described in Table 1. From July 2011 to July 2021, 236 cases of non-neonatal tetanus were included, with a gender ratio (male/female) of 1.07. The median age of patients was 60.50 years (IQR, 21.00 years), and the median age of males (56.00 years) was lower than that of females (67.00 years). The majority of the patients were elderly. In China, Diphtheria-Tetanus-Pertussis (DTP) vaccine has been a part of the national immunization program since 1978. Therefore, people born before 1978 and have not received vaccinations have lower immunity and may have multiple underlying diseases, making them more vulnerable to tetanus[9]. In terms of occupational distribution, farmers comprised the majority of the patients (67.80%), followed by workers (11.02%), retirees (8.90%), and laid-off/unemployed persons (5.93%). Among the 236 patients, the majority (91.53%) had no history of tetanus toxoid-containing vaccine (TTCV) vaccination, and the rest (8.47%) had completed full TTCV vaccination. The concentration of tetanus antibodies decreases with age, and most people do not maintain protective antibody levels until 10 years after vaccination[5,9]. Therefore, TTCV vaccination and regular booster doses are necessary for sustained and effective immunity.

    Table 1.  Basic characteristics and clinical data of patients with non-neonatal tetanus

    CharacteristicsNumber of casesComposition ratio (%)
    GenderMale12251.69
    Female11448.31
    Age [years, M (IQR)]Male56.00 (20.25)
    Female67.00 (19.00)
    OccupationFarmer16067.80
    Worker2611.02
    Retiree218.90
    Laid-off or unemployed145.93
    Fisherman62.54
    Freelance62.54
    Children20.84
    Professional skill worker10.42
    ResidenceUrban6728.39
    Rural16971.61
    Tetanus toxoid vaccinationNil21691.53
    Completed208.47
    Pathogenic factorsIdentified21189.41
    Traumatism19180.93
    Other risk factors208.47
    Unidentified2510.59
    Injury sitesLower extremity10644.92
    Upper extremity6326.69
    Head and neck3113.14
    Other sites3615.25
    Incubation period [d, M (IQR)]Head and neck5.00 (6.00)
    Trunk30.00 (0.00)
    Upper extremity7.00 (5.00)
    Lower extremity9.50 (10.25)
    Multiple sites7.00 (10.50)
    Initial diagnosisYes3213.56
    No20486.44
    The level of health facilities for initial visitProvince-level10142.80
    City-level6728.39
    County-level4418.64
    Private/village2410.17
    Time from onset to initial visit [d, M (IQR)]2.00 (4.00)
    First symptomsTrismus19984.32
    Muscle spasms93.81
    Myodynia62.54
    Nuchal rigidity41.70
    Dysphagia41.70
    Other symptom145.93
    Co-morbiditiesYes19582.63
    No4117.37
    ComplicationsYes19582.63
    No4117.37
    Length of a hospital stay [d, M (IQR)]16.00 (18.00)
    Hospitalization expenses [RMB, M (IQR)]20,200.34 (3,659.10)
    Payment methodSelf-paying13155.51
    Resident basic medical insurance5222.03
    Rural cooperative medical insurance4318.22
    Others104.24
    ICU admissionYes6125.85
    No17574.15
    Tracheal intubation or tracheotomyYes8033.90
    No15666.10

    From July 2011 to July 2021, non-neonatal tetanus occurred almost every month, with sporadic onset and no seasonality (Supplementary Figure S1A, available in www.besjournal.com). The number of cases did not show a significant change in the annual disease occurrence (Supplementary Figure S1B). Among the 236 patients, the overall case fatality was 11.44% (n = 27). Except for the period from July 2011 to June 2012, the case fatality exceeded 20.00%, and the case fatalities in most of the other annual periods fluctuated between 6.00% and 15.00%, showing a downward trend (Figure 1). This can be attributed to the comprehensive coverage of vaccination and improvements in intensive care conditions[3].

    Figure 1.  Trend of case fatality in non-neonatal tetanus patients over time (by year).

    Figure S1.  Temporal distribution of non-neonatal tetanus cases from July 2011 to July 2021. (A) The time of disease onset of non-neonatal tetanus patients (month, year). (B) Trend in the number of non-neonatal tetanus cases over time (by year).

    The pathogenic factors of the patients are shown in Table 1. Among the 236 patients, 211 (89.41%) cases had a clear pathogenic factor, while 25 (10.59%) cases did not specify a clear pathogenic factor. Among those with a clear pathogenic factor, 191 (80.93%) cases were caused by traumatic injuries. Other factors were oral infection, tumor rupture, drug injection, chronic skin ulcers, diabetic foot, indwelling gas cannula, minimally invasive surgery, and open surgery. Among the 191 trauma cases, 63 cases (26.69%) were cut wounds, 60 (25.42%) were puncture wounds, and 25 (10.59%) were fall injuries. In the diagnosis of tetanus, attention should be paid to the history of trauma and surgery and to other rare pathogenic factors to reduce clinical misdiagnosis and missed diagnoses[10].

    The patients’ disease severity and clinical characteristics are shown in Table 1. The median incubation period was 8.00 days (IQR, 9.00 days), ranging from 1.00 day to 7.00 years for the 236 tetanus patients. There was a significant difference in the incubation period among different injury sites (P < 0.05), and the incubation period of injuries in the head and neck was shorter than that in the lower limb (P < 0.05) (Supplementary Table S2, available in www.besjournal.com). The majority of cases presented typical initial symptoms, including trismus (84.32%), muscle convulsions (3.81%), muscle spasms (2.54%), stiff neck (1.70%), and dysphagia (1.70%). Of 236 patients, 32 cases (13.56%) were diagnosed for the first time, and 204 (86.44%) were not. The first diagnosis medical facilities were mainly at the county level (42.80%), city level (28.39%), and provincial level (18.64%), and a few were village level and private clinics. The time from onset to the initial visit ranged from 1.00 to 38.00 days, with a median of 2.00 days. Most patients (82.63%) had one or more co-morbidities and complications (Table 1). As shown in Supplementary Table S3 (available in www.besjournal.com) the most common co-morbidity was hypertension (10.17%), followed by tuberculosis (8.90%) and cerebrovascular disease (7.20%). The most common complication was secondary infection (67.37%), followed by respiratory failure (19.07%), electrolyte disturbances (16.10%), and hypoalbuminemia (14.41%). In combination with the fact that most of the patients came from rural areas, this indirectly reflects the inadequate level of medical care in primary healthcare facilities, the imperfections in intensive care, and the insufficient professional ability of medical staff.

    Table S2.  Comparison of latency at different etiological sites in non-neonatal tetanus patients

    Variables Head and neck Trunk Upper extremity Lower extremity Multiple sites χ2 value P value
    Incubation period [M (IQR)] 5.00 (6.00)a 30.00 (0.00) 7.00 (5.00) 9.50 (10.25) 7.00 (10.50) 18.39 < 0.01
      Note. Kruskal–Wallis test was used to compare incubation period among different etiological sites. aCompared with lower limb group.

    Table S3.  Co-morbidities and complications of patients with non-neonatal tetanus

    Characteristics Number of cases (persons) Composition ratio (%)
    Co-morbidities Hypertension 24 10.17
    Tuberculosis 21 8.90
    Cerebrovascular disease 17 7.20
    Chronic liver disease 14 5.93
    Coronary artery disease 7 2.97
    Diabetes 7 2.97
    Cancer 6 2.54
    AIDS 6 2.54
    Heart valve diseases 4 1.70
    Autoimmune rheumatic disease 4 1.70
    Arrhythmia 2 0.85
    Complications Secondary infection 159 67.37
    Respiratory failure 45 19.07
    Electrolyte disturbances 38 16.10
    Hypoalbuminemia 34 14.41
    Hypohepatia 31 13.13
    Myocardial injury 22 9.32
    Autonomic dysfunction 16 6.78
    Renal insufficiency 11 4.66
    Asphyxia 9 3.81
    Hypoxic-ischemic encephalopathy 8 3.39
    Sepsis 7 2.97
    Cardiac failure 5 2.11
    Acute pancreatitis 5 2.11
    Gastrointestinal hemorrhage 4 1.70
    Coagulation dysfunction 4 1.70
    Toxic encephalopathy 3 1.27
    Acute myocardial infarction 3 1.27
    Pressure ulcer 3 1.27
    Thrombogenesis 2 0.85

    According to the Ablett scale (Supplementary Table S1), 236 patients were divided into four groups: grade I (50 cases, 21.19%), grade II (110 cases, 46.61%), grade III (60 cases, 25.42%), and grade IV (16 cases, 6.78%). The proportion of patients with moderate and severe tetanus was higher than that reported in previous studies[10]. This may be attributed to the referrals from other hospitals, as patients with severe tetanus who cannot be adequately treated are typically transferred from lower-level hospitals to higher-level ones. Univariate analysis showed that there were significant differences in the time from onset to treatment, incubation period, forms of tetanus, combined diabetes, and cancer among different grading of disease severity groups (P < 0.05) (Table 2). Multivariate ordered logistic regression analysis showed that systemic tetanus (OR = 26.79, 95% CI: 9.24–77.63, P < 0.01) was the positive factor for the disease severity, and diabetes mellitus (OR = 0.15, 95% CI: 0.03–0.72, P = 0.02) was the negative factor for the disease severity (Table 2).

    Table 2.  Risk factors on grading disease severity in non-neonatal tetanus patients

    Variables Grading of disease severity Univariate analysis Multivariate
    analysis
    Grade I, n (%) Grade II, n (%) Grade III, n (%) Grade IV, n (%) χ2 value P value OR (95% CI) P value
    Age [years, M (IQR)] 59.50 (19.25) 59.00 (21.25) 66.00 (19.25) 58.50 (23.50) 2.52 0.47
    Time from onset to initial visit
    [d, M (IQR)]
    3.50 (6.00) 3.00 (4.00) 2.00 (2.00) 1.00 (1.00) 16.43 < 0.01 0.97 (0.89, 1.06) 0.50
    Incubation period [d, M (IQR)] 7.00 (9.00) 9.00 (11.00) 7.00 (5.00) 6.50 (10.00) 10.44 0.02 1.00 (1.00, 1.00) 0.07
    Gender 0.16 0.98
    Male 26 (21.31) 56 (45.90) 31 (25.41) 9 (7.38)
    Female 24 (21.05) 54 (47.37) 29 (25.44) 7 (6.14)
    Forms of tetanus 50.62 < 0.01
    Localized/cerebral 22(81.48) 4 (14.82) 1 (3.70) 0 (0.00) 1.00
    Systemic 28 (13.40) 106 (50.72) 59 (28.23) 16 (7.65) 26.79 (9.24, 77.63) < 0.01
    Co-morbidities
    Chronic liver disease 1 (7.14) 9 (64.29) 3 (21.43) 1 (7.14) 2.36 0.47
    Tuberculosis 5 (23.81) 8 (38.10) 7 (33.33) 1 (4.76) 1.20 0.76
    Hypertension 3 (12.50) 11 (45.83) 8 (33.33) 2 (8.33) 1.88 0.60
    Coronary artery disease 1 (14.29) 3 (42.86) 2 (28.57) 1 (14.29) 1.49 0.71
    Heart valve diseases 2 (50.00) 0 (0.00) 2 (50.00) 0 (0.00) 4.88 0.13
    Arrhythmia 0 (0.00) 1 (50.00) 1 (50.00) 0 (0.00) 1.68 1.00
    Autoimmune rheumatic disease 1 (25.00) 2 (50.00) 1 (25.00) 0 (0.00) 0.65 1.00
    Cerebrovascular disease 5 (29.41) 5 (29.41) 5 (29.41) 2 (11.77) 3.19 0.33
    Diabetes 0 (0.0) 2 (28.57) 3 (42.86) 2 (28.57) 6.53 0.05 0.15 (0.03, 0.72) 0.02
    Cancer 4 (66.67) 0 (0.00) 0 (0.00) 2 (33.33) 13.57 < 0.01 3.32 (0.46, 23.81) 0.23
    AIDS 0 (0.00) 3 (50.00) 2 (33.33) 1 (16.67) 2.78 0.35

    Patients were divided into two groups based on whether they survived (n = 209, 88.56%) or died (n = 27, 11.44%) (Supplementary Table S4, available in www.besjournal.com). Univariate analysis of risk factors for disease outcome showed that there were significant differences between the two groups in the time from onset to treatment, incubation period, tracheal intubation or tracheotomy, grading of disease severity, diabetes mellitus, hypoxic-ischemic encephalopathy, secondary infection, respiratory failure, asphyxia, cardiac failure, myocardial injury, acute myocardial infarction, acute pancreatitis, and renal insufficiency (all P < 0.05) (Supplementary Table S4). The above factors were then included in binary multivariate regression analysis showing that grading of disease severity (OR = 54.97, 95% CI: 5.55–544.15, P < 0.01), complicated with respiratory failure (OR = 14.19, 95% CI: 1.84–109.36, P = 0.01), complicated with asphyxia (OR = 84.18, 95% CI: 3.62–1,959.83, P < 0.01), cardiac failure (OR = 279.68, 95% CI: 4.31–18,140.28, P < 0.01), or renal insufficiency (OR = 84.45, 95% CI: 2.30–3,104.41, P = 0.02) were significantly associated with the risk of death in non-neonatal tetanus patients (Supplementary Table S5, available in www.besjournal.com), which is consistent with previous studies[5,8,10]. The care of tetanus patients will continue to present challenges in the future.

    Table S4.  Univariate analysis of risk factors of disease outcome in non-neonatal tetanus patients

    VariablesOutcomeχ2/Z valueP value
    Died, n (%)Alive, n (%)
    Age [years, M (IQR)]63.00 (23.00)60.00 (20.00)−1.24a0.22
    Time from onset to initial visit [d, M (IQR)]1.00 (1.00)3.00 (4.00)−3.22a< 0.01
    Incubation period [d, M (IQR)]5.50 (7.00)8.00 (10.00)−2.43a0.02
    Gender0.18b0.67
    Male15 (12.30)107 (87.70)
    Female12 (10.53)102 (89.47)
    Forms of tetanus2.77b0.10
    Systemic27(12.92)182 (87.08)
    Localized/Cerebral0 (0.00)27 (100.00)
    ICU admission1.99b0.16
    No17 (9.71)158 (90.29)
    Yes10 (16.39)51 (83.61)
    Tracheal intubation or tracheotomy18.10b< 0.01
    No8 (5.13)148 (94.87)
    Yes19 (23.75)61 (76.25)
    Grading of disease severity64.80b< 0.01
    I0 (0.00)50 (100.00)
    II1 (0.91)109 (99.09)
    III15 (25.00)45 (75.00)
    IV11 (68.75)5 (31.25)
    Co-morbidities
    Chronic liver disease1 (7.14)13 (92.86)0.01b0.93
    Tuberculosis0 (0.00)21 (100.00)1.87b0.17
    Hypertension2 (8.33)22 (91.67)0.03b0.87
    Coronary artery disease1 (14.29)6 (85.71)0.58
    Heart valve diseases0 (0.00)4 (100.00)1.00
    Arrhythmia0 (0.00)2 (100.00)1.00
    Autoimmune rheumatic disease0 (0.00)4 (100.00)1.00
    Cerebrovascular disease3 (17.65)14 (82.35)0.19b0.66
    Diabetes3 (42.86)4 (57.14)0.03
    Cancer2 (33.33)4 (66.67)0.14
    AIDS2 (33.33)4 (66.67)0.14
    Complications
    Hypoxic-ischemic encephalopathy4 (50.00)4 (50.00)0.01
    Toxic encephalopathy0 (0.00)3 (100.00)1.00
    Secondary infection24 (15.09)135 (84.91)6.42b0.01
    Respiratory failure21 (46.67)24 (53.33)68.10b< 0.01
    Asphyxia8 (88.89)1 (11.11)47.73b< 0.01
    Cardiac failure3 (60.00)2 (40.00)0.01
    Myocardial injury6 (27.27)16 (72.73)4.40b0.04
    Acute myocardial infarction2 (66.67)1 (33.33)0.04
    Gastrointestinal hemorrhage0 (0.00)4 (100.00)1.00
    Acute pancreatitis3 (60.00)2 (40.00)0.01
    Hypohepatia6 (19.35)25 (80.65)1.40b0.24
    Renal insufficiency7 (63.64)4 (36.36)25.86b< 0.01
    Electrolyte disturbances6 (15.79)32 (84.21)0.41b0.52
    Hypoalbuminemia5 (14.71)29 (85.29)0.13b0.72
    Coagulation dysfunction0 (0.00)4 (100.00)1.00
    Pressure ulcer1 (33.33)2 (66.67)0.31
    Sepsis2 (28.57)5 (71.43)0.19
    Thrombogenesis0 (0.00)2 (100.00)1.00
      Note. aRepresents the Z values derived from Mann-Whitney U test. bRepresents the χ2 values derived from chi-squared test. Fisher’s exact probability test was used for the remaining variables.

    Table S5.  Binary logistic regression analysis of risk factors for disease outcome in non-neonatal tetanus patients

    VariablesOR95% CIP value
    Time from onset to initial visit1.11(0.91, 1.36)0.30
    Incubation period1.00(0.99, 1.01)0.72
    Tracheal intubation or tracheotomy0.36(0.02, 6.58)0.49
    Grading of disease severity54.97(5.55, 544.15)< 0.01
    Diabetes13.72(0.61, 310.75)0.10
    Hypoxic-ischemic encephalopathy0.44(0.03, 6.51)0.55
    Secondary infection0.12(0.00, 19.36)0.41
    Respiratory failure14.19(1.84, 109.36)0.01
    Asphyxia84.18(3.62, 1,959.83)< 0.01
    Cardiac failure279.68(4.31, 18,140.28)< 0.01
    Myocardial injury0.41(0.02, 8.54)0.56
    Acute myocardial infarction19.21(0.04, 9,514.50)0.35
    Acute pancreatitis8.60(0.43, 172.56)0.16
    Renal insufficiency84.45(2.30, 3,104.41)0.02

    The median length of hospital stay was 16.00 days (IQR, 18.00 days; range, 1.00–80.00 days). Self-payment (55.51%), resident basic medical insurance (22.03%), and rural cooperative medical insurance (18.22%) were the main payment methods (Table 1). The hospitalization cost ranged from RMB 733.10 to RMB 413,902.00 (~$107 − $60,188), with a median of RMB 20,200.34 (~$2,937). App one-fourth of the patients (25.85%) were admitted to the ICU, and the rate of tracheal intubation or tracheotomy was 33.90% (Table 1). There was a significant correlation between grading of disease severity and length of hospital stay (r = 0.28, P < 0.05), hospitalization expenses (r = 0.41, P < 0.05), ICU admission rate (r = 0.58, P < 0.05), and tracheal intubation or tracheotomy rate (r = 0.71, P < 0.05) (Supplementary Table S6, available in www.besjournal.com). These data imply that tetanus treatment is both time-consuming and expensive, particularly for severe cases. Therefore, clinical treatments for non-neonatal tetanus must be optimized and enhanced to further reduce case fatality and disease burden.

    Table S6.  Correlation analysis of grading of disease severity in non-neonatal tetanus patients

    Variablesr value
    Length of hospital stay0.28*
    Hospitalization expenses0.41*
    ICU admission rate0.58*
    Tracheal intubation or tracheotomy rate0.71*
      Note. Spearman analysis was used for the correlation analysis. *P value < 0.05.

    One advantage of this study is that the data came from medical digital records, ensuring accuracy and reliability. Second, this study could fill the gap in China’s epidemiological and disease burden data. There are also some limitations in this study. The case investigation covered few medical facilities, resulting in a relatively small sample size. In addition, our results are based on a retrospective analysis of existing data, making it difficult to draw causative conclusions.

    In Guangxi, China, the incidence of non-neonatal tetanus has been sporadic during 2011–2021, with a relatively low case fatality, which reflects the relatively high level of local medical facilities and technologies for tetanus. Having no vaccination history may be an important factor in the incidence of non-neonatal tetanus. Systemic tetanus was an independent factor for the disease severity. Grading of disease severity, complications with respiratory failure, asphyxia, cardiac failure, or renal insufficiency were significantly associated with the risk of death in non-neonatal patients. These data and findings provide basic information for the prevention and clinical treatment of non-neonatal tetanus in China, highlighting the need for continued efforts in improving vaccine coverage.

    No potential conflicts of interest were disclosed.

    The authors acknowledge all the participants and clinical/research staff from the Fourth People’s Hospital of Nanning, Guangxi International Zhuang Medical Hospital, and the Second Affiliated Hospital of Guangxi Medical University for their contribution to data collection.

    Study concept and design: THM, YL, and LJY. Methodology: THM, ZXL, DSQ, and THL. Data collection: MGF, ZXL, YSX, and THL. Formal analysis and data curation: MGF, KYW, YZX, and MCY. Writing - original draft: KYW and MGF. Writing – review and editing: YL, THM, LJY, and KYW. All the authors listed have made substantial contributions to the work and approved it for publication. All authors read and approved the final manuscript.

参考文献 (10)
补充材料:
23073+Supplementary Materials.pdf

目录

    /

    返回文章
    返回